While the trials were negative clinically, presenters and discussants noted biomarker changes consistent with reduced neuroinflammation (e.g., decreases in highsensitivity CRP) and other Alzheimersrelated signalsmodest but statistically significant effects that did not yield measurable cognitive benefit
doi: 10.1136/bmjopen-2023-072707 21 ProbstLMonneratSVogtDRLengsfeldSBurkardTMeienbergAet al
Lastly, for patients with significant high-end metabolic issues, sleep apnea, heart disease, uncontrolled hypertension, or immobility due to high BMI, GLP-1s alone may not be enough
An example is the publication of Order #97/2025 , which restricted the importation of GLP-1 receptor antagonist APIs
Meanwhile, factors such as age, heart failure, and previous stroke did not appear to change the overall trend
Here diet is an essential management strategy and fasting is strictly avoided to guarantee a sufficient glucose pool for energy metabolism